Graves' Disease Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight

Graves' Disease companies are TSHR Septerna, Cyclopeptides advanceCOR, EVOQ Therapeutics, Worg Pharmaceuticals, AV7 Limited, Novartis, Immunovant Sciences GmbH, and others.
(Albany, United States) As per DelveInsight's assessment, globally, Graves' Disease pipeline constitutes 8+ key companies continuously working towards developing 10+ Graves' Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Graves' Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graves' Disease Market.

The Graves' Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Download sample report to know in detail about emerging drugs @ Graves' Disease Pipeline Insight [https://www.delveinsight.com/sample-request/graves-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key takeaways from the Graves' Disease Pipeline Report:

* Graves' Disease Companies across the globe are diligently working toward developing novel Graves' Disease treatment therapies with a considerable amount of success over the years.
* Graves' Disease companies working in the treatment market are TSHR Septerna, Cyclopeptides advanceCOR, EVOQ Therapeutics, Worg Pharmaceuticals, AV7 Limited, Novartis, Immunovant Sciences GmbH, and others, are developing therapies for the Graves' Disease treatment

* Emerging Graves' Disease therapies in the different phases of clinical trials are- Research Program, WP-1302, K1-70, CFZ533, Batoclimab, and others are expected to have a significant impact on the Graves' Disease market in the coming years.
* In May 2025, Amgen has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved TEPEZZA Registered (teprotumumab) for marketing, making it the first authorized treatment specifically indicated for adult patients with moderate-to-severe Thyroid Eye Disease (TED).
* In May 2025, Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company dedicated to advancing and commercializing potentially best-in-class therapies for serious and rare diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to veligrotug ("veli"), its lead anti-IGF-1R drug candidate for the treatment of thyroid eye disease (TED).
* In January 2025, Sling Therapeutics, Inc., a late-stage biopharmaceutical company developing oral therapies for thyroid eye disease (TED), has announced topline efficacy and safety results from the Phase 2b/3 LIDS trial evaluating linsitinib in patients with active, moderate to severe TED. Linsitinib, the company's lead oral small molecule candidate taken twice daily, targets the well-established IGF-1R pathway. It has demonstrated a favorable safety profile, having been tested in over 900 patients across 15 clinical trials for various conditions.
* In December 2024, Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company dedicated to developing potentially best-in-class therapies for serious and rare conditions, has announced positive topline results from its Phase 3 THRIVE-2 clinical trial. The study evaluated veligrotug (veli), an intravenously administered anti-IGF-1R antibody, in patients with chronic thyroid eye disease (TED)-an autoimmune disorder marked by inflammation, tissue expansion, and damage around the eyes.

Graves' Disease Overview

Graves' Disease is an autoimmune disorder that leads to the overproduction of thyroid hormones, a condition known as hyperthyroidism. Graves' Disease occurs when the immune system mistakenly attacks the thyroid gland, causing it to become overactive. Graves' Disease is the most common cause of hyperthyroidism, especially in women under 40. Graves' Disease symptoms include weight loss, rapid heartbeat, anxiety, tremors, goiter (enlarged thyroid), and bulging eyes (Graves' ophthalmopathy). Graves' Disease diagnosis typically involves blood tests to measure thyroid hormone levels and thyroid-stimulating immunoglobulins, along with imaging studies like radioactive iodine uptake scans.

Graves' Disease treatment options include antithyroid medications (such as methimazole), radioactive iodine therapy, and thyroid surgery in severe cases. Graves' Disease management may also involve treating eye-related complications and addressing associated mental health concerns. Graves' Disease can significantly impact quality of life if left untreated, making early diagnosis and intervention critical. Graves' Disease prognosis varies, but with proper treatment, most patients achieve symptom control and improved well-being. Graves' Disease research continues to explore new therapies and a better understanding of its underlying mechanisms. Graves' Disease awareness is crucial for early detection, especially in individuals with a family history or other autoimmune conditions.

Get a Free Sample PDF Report to know more about Graves' Disease Pipeline Therapeutic Assessment - Graves'disease pipeline outlook [https://www.delveinsight.com/report-store/graves-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Emerging Graves' Disease Drugs Under Different Phases of Clinical Development Include:

* Research Program: TSHR Septerna
* Research Program: Cyclopeptides advanceCOR
* Research Program: EVOQ Therapeutics
* WP-1302: Worg Pharmaceuticals
* K1-70: AV7 Limited
* CFZ533: Novartis Pharmaceuticals
* Batoclimab: Immunovant Sciences GmbH

Graves' Disease Route of Administration

Graves' Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical

Graves' Disease Molecule Type

Graves' Disease Products have been categorized under various Molecule types, such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Graves' Disease Pipeline Therapeutics Assessment

* Graves' Disease Assessment by Product Type
* Graves' Disease By Stage and Product Type
* Graves' Disease Assessment by Route of Administration
* Graves' Disease By Stage and Route of Administration
* Graves' Disease Assessment by Molecule Type
* Graves' Disease by Stage and Molecule Type

Further Graves' Disease product details are provided in the report. Download the Graves' Disease pipeline report to learn more about the emerging Graves' Disease therapies [https://www.delveinsight.com/sample-request/graves-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

DelveInsight's Graves' Disease Report covers around 10+ products under different phases of clinical development like

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration

Some of the key companies in the Graves' Disease Therapeutics Market include:

Key companies developing therapies for Graves' Disease are - Jubilant Pharma Holdings Inc., Novartis, Sun Pharma, Pfizer, F. Hoffmann-La Roche Ltd., Abbott, Thermo Fisher Scientific Inc., Institute of Isotopes Co. Ltd., bioMerieux SA, Horizon Therapeutics Ireland DAC, and others.

Graves' Disease Pipeline Analysis:

The Graves' Disease pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Graves' Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graves' Disease Treatment.
* Graves' Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Graves' Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graves' Disease market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Graves' Disease drugs and therapies [https://www.delveinsight.com/sample-request/graves-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Graves' Disease Pipeline Market Drivers

* Increasing the prevalence of Graves' Disease, increased public awareness about the treatment of Graves'' disease are some of the important factors that are fueling the Graves' Disease Market.

Graves' Disease Pipeline Market Barriers

* However, high cost of the treatment, complications associated with the treatment and other factors are creating obstacles in the Graves' Disease Market growth.

Scope of Graves' Disease Pipeline Drug Insight

* Coverage: Global
* Key Graves' Disease Companies: TSHR Septerna, Cyclopeptides advanceCOR, EVOQ Therapeutics, Worg Pharmaceuticals, AV7 Limited, Novartis, Immunovant Sciences GmbH, and others
* Key Graves' Disease Therapies: Research Program, WP-1302, K1-70, CFZ533, Batoclimab, and others
* Graves' Disease Therapeutic Assessment: Graves' Disease current marketed and Graves' Disease emerging therapies
* Graves' Disease Market Dynamics: Graves' Disease market drivers and Graves' Disease market barriers

Request for Sample PDF Report for Graves' Disease Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/graves-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Graves' Disease Report Introduction

2. Graves' Disease Executive Summary

3. Graves' Disease Overview

4. Graves' Disease- Analytical Perspective In-depth Commercial Assessment

5. Graves' Disease Pipeline Therapeutics

6. Graves' Disease Late Stage Products (Phase II/III)

7. Graves' Disease Mid Stage Products (Phase II)

8. Graves' Disease Early Stage Products (Phase I)

9. Graves' Disease Preclinical Stage Products

10. Graves' Disease Therapeutics Assessment

11. Graves' Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Graves' Disease Key Companies

14. Graves' Disease Key Products

15. Graves' Disease Unmet Needs

16 . Graves' Disease Market Drivers and Barriers

17. Graves' Disease Future Perspectives and Conclusion

18. Graves' Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graves-disease-clinical-trials-2025-ema-pdma-fda-approvals-medication-therapies-treatment-market-mechanism-of-action-route-of-administration-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.